Answers are grounded in this paper and cite their sources.
Demonstrates successful reprogramming of patient blood cells with a homozygous PLA2G6 mutation into pluripotent stem cells, providing a novel cellular model for early-onset Parkinson's disease.
A recessive mutation in PLA2G6, which is known to cause a heterogeneous neurodegenerative clinical spectrum, has recently been shown to be responsible for autosomal-recessive familial forms of Parkinson's disease (PD). Here, we generated induced pluripotent stem cells (iPSCs) from the peripheral blood mononuclear cells of a female patient with a homozygous PLA2G6 c.991G > T (p.D331Y) mutation by using the Sendai-virus delivery system. The resulting iPSCs showed pluripotency confirmed by immunofluorescent staining for pluripotency markers and differentiated into the 3 germ layers in vivo. This cellular model will provide a good resource for further pathophysiological studies of PD.
No takes yet. Share an insight, caveat, or question.
Cheng et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: